Definitive Contract 75F40121C00178
Award Date
9/16/21
Potential Completion Date
3/31/25
Potential Value
$555K
Federal Agency
Food and Drug Administration
Awardee
The University Of Auckland
Ultimate Awardee
Not listed
NAICS Category
611310 - Colleges, Universities, and Professional Schools
PSC Category
B537 - Special Studies/Analysis- Medical/Health
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Silver Spring, MD 20993, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
3
Legislative Mandate
Service Contract Act
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Food and Drug Administration (FDA) awarded a $298,583.09 definitive contract to The University of Auckland Research Office Division, a state-controlled institution of higher learning based in New Zealand, to evaluate the applicability of a robotic soft esophagus (ROSE) device in assessing the swallowability of opioid drugs under normal and pathological conditions. This contract was issued under the FDA's Broad Agency Announcement for Advanced Regulatory Science, which solicits...
This contract was awarded by the National Aeronautics and Space Administration (NASA) Shared Services Center to the University of Auckland in New Zealand. The $109,371.00 firm fixed-price purchase order is for research and development services. The University of Auckland, a non-profit educational institution, has previously supported federal agencies through contracts and grants, including work for the Food and Drug Administration (FDA) on pharmaceutical testing and for the U.S. Agency for...
This federal contract award, valued at $399,988.00, was issued by the Food and Drug Administration (FDA) to Monash University, a non-profit research university in Australia. The contract is for a study titled "Bridging the Gap Between Urinary Tract Infection Pharmacokinetic/Pharmacodynamic In Vitro Models and the Optimization of Antibiotic Selection, Dosing Strategies, Clinical Breakpoints, and Novel Drug Development." The contract has a performance period through September 28, 2026...
This is a $997,996.00 definitive contract awarded by the Food and Drug Administration (FDA) to the University of Texas at Austin (UT Austin) for research on the "Correlation Between Material Properties, Manufacturing Process, Structural Properties, and Quality Attributes of Long-Acting, Biodurable Implants". The contract has no set-aside designation and is scheduled for completion by December 15, 2026. UT Austin is a prominent public research university that frequently supports federal...
This federal contract award was issued by the Food and Drug Administration (FDA), a civilian agency, to The University of Iowa, a large public research university. The contract is for "OTHER MEDICAL (APPLIED/EXPLORATORY)" services and has a ceiling value of $84,541.69. It is a definitive contract with a cost-no-fee pricing type. The contract is designated as an 8(a) sole source set-aside, indicating it was awarded to a small disadvantaged business under the Small Business...
This is a $1,417,987.00 federal contract awarded by the Food and Drug Administration (FDA) to the University of Connecticut (UConn). The contract is a Definitive Contract without a set-aside designation. The contract involves a comparative trial of different packaging components of an opioid packaging solution to evaluate their impact on opioid safety outcomes. UConn is working with Hartford Hospital and the UConn Health Center as subcontractors on this research project, which aims to identify...
This firm fixed-price purchase order, valued at $150,120.00, was awarded by the Food and Drug Administration (FDA) to Kobenhavns Universitet, a university in Copenhagen, Denmark. The contract is for research services to explore in vitro methods and pulsatile microdialysis for product characterization for young infants and neonates. The contract does not have a set-aside designation. Kobenhavns Universitet has received over $3 million in federal grant funding from agencies such as the...
This federal contract, awarded by the Food and Drug Administration (FDA) to the Regents of the University of Michigan, is a $2,235,290.00 firm fixed-price definitive contract to conduct a comprehensive study on stimulant and opioid use and use disorder trajectories and associated consequences in U.S. adults. The contract does not have a set-aside designation. The University of Michigan, as the prime contractor, will leverage its extensive research capabilities to carry out this study. Two...
The University of Connecticut (UConn) has been awarded a $1,103,886 firm-fixed-price definitive federal contract by the Food and Drug Administration (FDA) for research and development related to the impact of active pharmaceutical ingredients on in situ forming implants and understanding in vitro and in vivo performance differences. This contract, which has a completion date of September 29, 2026, was issued under the FDA's Broad Agency Announcement for research and development to support...
The U.S. Food and Drug Administration (FDA) awarded a $687,062 firm-fixed-price contract to the University of Sydney, doing business as the International Clinical Trials Symposium, for the development of a laser-based testing platform for generic dry powders. This definitive contract has a completion date of September 20, 2025. The University of Sydney is a leading Australian educational institution that frequently receives federal contracts and grants from various U.S. government agencies,...